Phase IIb Study of BAY58-2667 (150/100/50 ug/h) IV in Acute Decompensated Chronic Congestive Heart Failure
Acute Heart Failure
Enrolment: 12 · Results not recorded
Loading the evidence…
Drug · Soluble guanylate cyclase activator
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Acute Heart Failure
Enrolment: 12 · Results not recorded
Congestive Heart Failure
Enrolment: 150 · Results not recorded
Acute Heart Failure
Enrolment: 5 · Results not recorded
Heart Failure · Heart Decompensation
Enrolment: 62 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Inspiratory resistive breathing produced by tracheal banding restricting tracheal surface area to 50% for 24 h
Soluble guanylyl cyclase activation with BAY 58-2667 prevented and, when given 24 h after resistive breathing, reversed the established lung injury, whereas sGC inhibition or sGC alpha1 deficiency exacerbated it.
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.